History
A unique story, since 1996
Our story starts back in 1996 when the approval of Law no. 425 of 8th August heralded the era of generic medicines. DOC was founded with the decision to join forces by three leading pharmaceutical groups: Chiesi Farmaceutici, Zambon and Apotex, which was already a leader in the manufacture and distribution of generic medicines in the USA.
Between 1996 and 2001, we laid the foundations for the management, organisation and production that were to make us one of the pioneers of the generic drugs market.
In 2013 In 2013, we were acquired by Charterhouse Capital Partners LLP, one of Europe’s leading and oldest private equity funds, marking what was this important group’s first investment in Italy.
This acquisition gave us the opportunity to maintain our independence and continue investing in the cornerstones of our success: privileging Italy and Europe for the manufacture of medicinal products, guaranteeing access to high-quality medicinal products and maintaining a high standard of communication with all stakeholders.
In 2016 the acquisition by CVC Capital Partners, one of the world's leading private investment companies, allows DOC to maintain its independence, privileging Europe and particularly Italy in the production of generic drugs.
In 2017 we established the Doc Ofta Business Unit, a new facility specialising in ophthalmology, to serve the needs of ophthalmologists and their patients.
In 2019 we were acquired by IGC Europe in partnership with Merieux Equity Partners. Another important milestone, that once again allowed us to maintain our independence whilst consolidating our leadership position and continuing to face future challenges with pride and optimism.
TPG Capital acquires majority stake in DOC Generici. With TPG's industry experience and support of our strategic vision, we can further consolidate our expertise in the pharmaceutical world and enter our next chapter of growth. DOC acquires Medivis product portfolio
DOC strengthens its second market position by signing an agreement to acquire Muscoril®, a muscle relaxant previously marketed by Sanofi.